Skip to main content
PRIPrimerica, Inc.Buy Wait6.5·$279.06
PRI · Why this verdict

Why Primerica (PRI) is rated BUY WAIT

Updated

Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results. How we score · Editorial policy

Show full disclosure ▾

About TrendMatrix. TrendMatrix is a publisher of general securities research and market commentary. We publish on a regular schedule. All content is the same for every subscriber in a tier — we do not provide personalized investment advice and we do not take into account any individual subscriber's financial situation, investment objectives, risk tolerance, tax situation, or holdings.

Not investment advice. TrendMatrix is not a registered investment adviser. Our content is for informational and educational purposes only. Consult your own licensed investment adviser, broker, or tax professional before making any investment decision.

Conflicts and positions. People who build TrendMatrix, or entities they control, may hold positions, long or short, in securities it covers, and may trade them at any time. Positions are not disclosed individually. Verdicts are generated by an automated model applied by the same rules to every covered stock, and are not adjusted for any position held by the people who build TrendMatrix. We do not accept payment from issuers for coverage.

No paid promotion. TrendMatrix does not accept payment from any issuer, broker, or third party in exchange for coverage of any security.

No fiduciary duty. No fiduciary, advisory, or agency relationship is created between you and TrendMatrix by reading our content or subscribing to our service.

Performance. Past performance is not indicative of future results. Performance figures reflect the published model only and do not reflect any individual subscriber's actual results.

Methodology · Editorial policy & full disclaimer

VerdictBUY WAIT
Overall score6.5/10
ConfidenceHIGH
MacroRISK_OFF
TrendMatrix Research · core thesis

Engine thesis — one sentence

Primerica is a high-quality life insurance and financial products compounder with 33% ROE, 23% margins and a 4-of-4 earnings beat streak, but the price is within 2.6% of the analyst target so the setup suggests waiting for a pullback.

Falsifiable statement — pillar-level invalidators below. Engine-derived; not personalized advice.

Thesis pillars

Primerica relies on reinsurance for 90% of mortality risk and on a very limited number of mortgage lenders, creating counterparty concentration.

↓Deteriorating
Bear case
Expectation
Reinsurance arrangements and lender relationships stay in place without worse terms over the next 12 months.

CounterThe failure or repricing of a main reinsurer could suddenly raise capital needs and cut earnings given how much risk is ceded.

Primerica earns an excellent 33% ROE with 23% margins and 130% free cash flow conversion of net income, backed by a wide economic moat.

→Stable
Quality breakdown
Expectation
ROE stays above 25% and free cash flow stays at or above 100% of net income over 12 months.

CounterPeer-relative growth is middling and the high ROE depends on a favorable reinsurance structure that may not hold.

Primerica has beaten EPS estimates in 4 straight quarters with an average surprise of 9.6%, most recently $6.41 versus $6.01 expected.

↓Deteriorating
Catalyst breakdown
Expectation
EPS keeps beating estimates in the November 2026 report and later quarters.

CounterEarnings in 11 days may already be priced in, and a stock below its 200-day average could fall even on a modest beat.

The stock trades at a forward P/E of 10.1x with a PEG of 0.52 and a dividend aristocrat yield of 1.8%.

↑Improving
Valuation breakdown
Expectation
Earnings growth holds the forward P/E at or below 11x while the dividend continues to rise.

CounterValue rank versus peers is weak at about 3.2/10, so the stock is cheap against its own history more than against competitors.

The $274.43 price is 2.6% below the $281.59 analyst target, leaving reward-to-risk of only 0.52 against 5.0% downside to the stop.

↑Improving
Upside pct
Expectation
Earnings growth lifts the analyst target above $300, restoring upside above 10%.

CounterLimited upside combined with the price already below its 200-day average argues for waiting for a pullback toward the $260.71 entry.

Per-dimension breakdown

Value

8.0/10data confidence 100%
ComponentSub-score
P/E8.8
P/S8.6
EV/EBITDA6.7
Fwd P/E9.2
PEG9.8
Analyst target5.0
  • ▸Forward P/E: 10.3x
  • ▸PEG: 0.53
  • ▸Attractively valued

Quality

8.5/10data confidence 100%
ComponentSub-score
ROE10.0
ROA3.1
Gross margin10.0
Op margin10.0
Net margin10.0
Current ratio9.3
FCF quality9.3
Moat7.6
Rule of 405.5
Piotroski F10.0
  • ▸Excellent ROE: 33%
  • ▸Strong margins: 23%
  • ▸Excellent cash conversion: 130% FCF/NI
  • ▸Wide economic moat

Growth

5.3/10data confidence 67%
ComponentSub-score
Rev growth4.7
EPS growth5.9

Momentum

7.4/10data confidence 100%
ComponentSub-score
RSI5.5
MACD10.0
OBV10.0
MA position7.0
Volume4.3
  • ▸Volume accumulation (rising OBV)
  • ▸Above 200-day MA

Sentiment

5.7/10data confidence 100%
ComponentSub-score
LLM sentiment5.0
Analyst rating5.0
Price target7.2

Insider

4.7/10data confidence 50%
ComponentSub-score
materiality5.0
holder change4.4
  • ▸Insider selling (low materiality) — $1,130,572 (0.013% of mkt cap)

Peer rank

4.9/10data confidence 80%
ComponentSub-score
value rank3.2
quality rank8.7
growth rank4.0
  • ▸Superior ROE vs peers
  • ▸Best-in-class margins

Technical

5.4/10data confidence 100%
ComponentSub-score
bollinger4.7
support resistance4.4
52w position7.1

Risk (lower is worse)

6.6/10data confidence 100%
ComponentSub-score
short interest7.1
days to cover3.7
volatility7.6
implied vol6.8
beta7.7
debt equity6.7
  • ▸Concentration risks: 2 HIGH, 1 MED (10-K Item 1A — sized via position_sizing, validated via buy_confidence)

Catalyst

6.8/10data confidence 100%
ComponentSub-score
erm5.0
earnings history10.0
earnings timing5.0
surprise avg7.2
dividend safety8.5
news activity5.0
  • ▸Perfect beat streak: 4Q
  • ▸Earnings in 6 days
  • ▸Dividend aristocrat: 1.7% yield

How the verdict was assembled

Engine trigger

Fundamentals strong but target reached (0.9% upside).

Engine technical detail
verdict_path: L4:PATH_C_QUALITY_VALUE|V8:TARGET_REACHED|ENTRY_STICKY:WITHIN_BAND
Passed (6)
  • MOMENTUM:7.4>=5.5
  • INSIDER:OK
  • 8K:CLEAN
  • NEWS_EVENTS:NONE_RECENT
  • SEMI_CYCLE_PEAK:CLEAR
  • MATERIALS_CYCLE_PEAK:CLEAR
Failed (2)
  • ASYMMETRY:0.2<1.5@spot
  • EARNINGS_PROXIMITY:6d<=7d
Warning (0)

none

Reward-to-Risk
0.18
Upside
+0.9%
Downside
5.0%
Sizing output
STARTER

SetupRange Bound — RSI 56 mid-range, Bollinger mid-band

EdgeNo clear edge — No clear edge identified

SuitabilityModerate — Balanced profile

Investment implication

The C-path quality+value combination triggered the STRONG_BUY_WAIT verdict: quality 8.5 and value 8.0 both clear their thresholds, with asymmetric R:R of 0.18 supporting the read.

The strongest dimensions are Quality at 8.5, Value at 8.0, and Momentum at 7.4; the weakest are Insider at 4.7, Peer rank at 4.9, and Growth at 5.3. The V9 engine flagged 2 failed gates, producing an asymmetric reward-to-risk of 0.18 and an engine sizing output of STARTER.

What would invalidate the thesis

Falsifying conditions — when triggered, the corresponding pillar's thesis is invalidated.

  • P1Excellent Returns And Margins

    Trip ifROE falls below 22% from the current 33%.

  • P2Consistent Earnings Beat Streak

    Trip ifEPS surprise stays below 0% for 2 consecutive quarters.

  • P3Attractive Valuation And Dividend

    Trip ifForward P/E rises above 14x from the current 10.1x.

  • P4Price Near Analyst Target

    Trip ifPrice falls below the $250.05 stop level.

  • P5Reinsurance Counterparty Concentration

    Trip ifReinsured share of mortality risk falls below 70% or a reinsurer downgrade exceeds 2 rating notches.

Engine reasoning is mechanically derived from pipeline gate outputs. See decision view.

Home › Stocks › PRI › Why this verdict